Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

12.05.16

EyeGate Reports Positive Data from Third Stage of Phase 1b/2a Clinical Trial of EGP-437 in Cataract Surgery Patients

Company Plans to Initiate Randomized, Double-masked, Placebo-Controlled Study in First Half of 2017 WALTHAM, Mass., Dec. 05, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical...
Read more
11.22.16

FDA Confirms a 510(k) De Novo Path for EyeGate’s Device, the Ocular Bandage Gel, Following Pre-Submission Meeting

[h2]Top-Line Data from First-in-Human Pilot Study Expected by Year-End 2016[/h2] WALTHAM, Mass., November 17, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company...
Read more
11.02.16

EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 02, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and...
Read more
09.21.16

EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference

WALTHAM, Mass., Sept. 21, 2016 -- EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders...
Read more
09.13.16

EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense

Funds to Advance Pre-clinical Development of CMHA-S Ocular Bandage Film WALTHAM, Mass., September 13, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that...
Read more
09.06.16

EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference

WALTHAM, Mass., Sept. 06, 2016 -- EYEG (Nasdaq: EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of...
Read more
08.10.16

EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 10, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and...
Read more
08.01.16

EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients

WALTHAM, Mass., Aug. 01, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders...
Read more